The aim of this article is to briefly present progress in the development of the potent adenosine receptor (AR) antagonists with high selectivity for either A 1 , A 2A , or A 2B ARs. The structural requirements for each AR subtype were discussed as well as their potential therapeutic use. In the search for new AR antagonists, series of imidazo-, pyrimido-, and diazepino-purindione derivatives as well as oxazolo-, oxazino-, and oxazepino-purindiones were designed, synthesized, and preliminarily evaluated in pharmacological studies. Oxygencontaining tricyclic derivatives were shown to be moderately potent AR antagonists exhibiting selectivity either for A 1 or A 2A ARs. Tricyclic purindiones with nitrogen in the third ring were generally more A 2A AR selective. The compounds tested in vivo according to the Antiepileptic Drug Development Program of the National Institutes of Health (USA) were generally active as anticonvulsants in chemically induced seizures.
BG-9719, KW-3902, and FK-838 are under development as drugs for treating renal failure (diuretics) [17, 18] and CPX for the treatement of cystic fibrosis [19] . Due to the greater solubility in water of FK-838 sodium salt, this compound has shown improved oral bioavailability as compared to FK-453, although FK-453 affinity and selectivity toward A 1 ARs was better (A 1 -pK i = 8.18; A 2A -pK i = 5.92 for FK 838 and A 1 -pK i = 9.31; A 2A -pK i = 5.90 for FK 453) [17] .
The analysis of structure-activity relationships of xanthines, the major group of A 1 -adenosine receptor antagonists, revealed the main requirements for their activity (Fig. 2) .
Although potent A 1 AR antagonists with high selectivity for the A 1 AR subtype have been developed in the last years, some of the compounds considered to be selective may not be as selective in humans as in rats and may not be very selective vs. the new AR subtypes A 3 or A 2B . Low water solubility of many A 1 AR antagonists remains a problem.
Recent developments in A 1 AR-selective antagonists include [20] mainly non-xanthine groups of compounds: thiazoles [21, 22] , thiadiazoles [21] , 3-benzoylothiophenes [23] , pyrazolopyridines [17] , 3-arylotriazinobenzimidazolones (ATBIs) [24] , 7-deazaadenines [25] and triazolo-quinazoline [26] , -quinoxaline [27] , -pyridazine [28] , and -pyrimidine [29] derivatives.
Several theoretical studies aimed at understanding the way ligands interact with the A 1 AR binding site [32, 33] were recently supplemented by Da Settimo's model [24] . In this approach, molecular modeling studies were performed based on a set of pharmacophoric elements of the well-known A 1 AR antagonists from different chemical classes and on a rhodopsin-based model of the bovine adenosine A 1 receptor. It was hypothesized that within the A 1 AR binding cleft exist three putative hydrogen bonding sites (HB 1 acceptor, HB 2 and HB 3 donors) and three lipophilic pockets (
Another way to analyze adenosine A 1 receptor activity uses selective irreversible antagonists of this AR subtype [30, 31] . Irreversible adenosine A 1 receptor antagonists (Fig. 3) [34, 35] . Central A 2A ARs are mainly located in parts of the basal ganglia such as striatum and are able to modulate the actions of dopamine receptors [36] [37] [38] . Furthermore, A 2A AR antagonists may be useful in the treatment of dementia, and other neurodegenerative disorders, alcohol withdrawal, ischemic conditions (such as stroke, cardiac ischemia), migraine, and pain [39] [40] [41] [42] .
A variety of xanthine derivatives, mainly 8-substituted, has shown A 2A AR antagonist properties [34, 42] . Introduction of a styryl group in the 8-position was critical in obtaining compounds with selec-tive A 2A AR antagonistic properties. As a result, the structurally related KF 17837 and its N,N-diethyl analog KW 6002 (Fig. 4) , were discovered. Despite having similar in vitro profiles (Fig. 4) , these two structurally similar xanthines appeared to have dramatically different in vivo potencies, as measured by the attenuation of haloperidol-induced catalepsy in mice, with KW-6002 being clearly more potent (ED 50 = 0.03 mg/kg and 2.7 mg/kg for KW-6002 and KF-17837, respectively). This divergence in in vivo activity may be due to differences in pharmacokinetics, pharmacodynamics, metabolism, and/or bioavailability. KW-6002 is undergoing phase II clinical trials for the potential treatment of Parkinson's disease and, since June 2000, for the treatment of depression [43, 44] . In order to obtain further A 2A -selective antagonists with high water solubility at physiological pH values, useful as pharmacological tools and potential drugs [45] [46] [47] , water-soluble prodrugs (e.g., MSX-3 from 8-styrylxanthine derivative MSX-2 [39] ) were obtained. MSX-2 has also been prepared in tritiated form as a radioligand for labeling A 2A ARs. The main drawback specific for this class of compounds is their low stability. In dilute solution they suffer from sensitivity to photoisomerization: the active (E)-configurated 8-styrylxanthines form isomeric mixtures in which often the less active or even inactive (Z)-isomer dominates.
Among highly potent and selective nonxanthine antagonists for A 2A ARs are derivatives of pyrazolotriazolopyrimidine SCH 58261 and triazolotriazine ZM 241385 (Fig. 4) ; both compounds have been tritiated for use as radioligands. [ 3 H]ZM 241385, an excellent radioligand for A 2A receptors, is of sufficiently high affinity at recombinant A 2B receptors for use as radioligand when these receptors are expressed in systems lacking A 2A receptors [44, 48] .
Second-generation pyrazolotriazolopyrimidines have been reported as potent and selective A 2A receptor antagonists [50] . Based on these results [ 11 C]SCH 442416, a new non-xanthine ligand was obtained and has been shown to be applicable for diagnostic positron tomography studies for in vivo measurement of A 2A ARs [51] .
Steric, electrostatic, and hydrophobic properties of the typical A 2A AR antagonists were discussed [34, 52] . Important features for A 2A affinity and selectivity are: voluminous, frequently aromatic substituent; hydrogen bond acceptor; and hydrogen bond donor (the latter does not appear in A 2A -selective 8-styrylxanthine derivatives [34] .
The A 2B receptor subtype is a low-affinity receptor, adenosine-exhibiting activity at this subtype at concentrations greater than 10 µM [1] . It is the least investigated subtype of ARs in consequence of lack of suitable, potent, and selective ligands for detailed study [9] . Recently it has been proposed that A 2B AR antagonists may have potential for use in the treatment of asthma, myocardial reperfusion injury, allergic reactions, autoimmune and inflammatory bowel diseases, and non-insulin dependent diabetes and retinopathy [16, 53] .
It is hypothesized that structurally related to CGS 15943 2-alkyl-8-aryl-9-methyl adenines (e.g., compounds 1 and 2) cause inhibition of hepatic glucose production via the A 2B receptor. These compounds are in preclinical study for the treatment of non-insulin dependent diabetes. However, the compounds are not A 2B selective.
The first potent antagonists at human A 2B AR were found in the group of 1,3-dialkylxanthines [54] . More selective and potent A 2B AR antagonists have been reported nowadays among 8-phenyl xanthine derivatives [53, 55] (Fig. 5) . MRS 1754 and MRS 1706 may be the first selective pharmacological probes needed to investigate the physiological role of this AR subtype and in tritiated form may be suitable tools for pharmacological A 2B receptor tests [55] . However, the compounds exhibit only low selectivity vs. rat A 1 ARs.
Structural predictions of adenosine A 2B antagonist affinity were done using molecular field analysis [56] . A pharmacophore model was developed using known A 2B antagonists, mainly xanthines. It was stated that a hydrogen bond donor in the 7-position of xanthine is essential for the biological activity. The presence of more negative charges on the N-1 increases biological activity, bulky aromatic substitutions on the 8-position improve activity.
To develop new ligands for A 2A ARs, two series of tricyclic compounds have been prepared: the group of oxygen-or nitrogen-containing annelated theophylline derivatives (Fig. 6) . So, oxazolo-(1), oxazino-(2), and oxazepino-purindiones (3) were obtained in the former group and imidazo-(4), pyrimido-(5), and diazepino-purindiones (6) were obtained as the latter group of compounds. The new compounds could be envisaged as bioisosteric analogs of 8-styryl xanthines. In contrast to styrylxanthines however, they cannot isomerize in dilute solution, due to their sterically fixed structure.
Compounds from groups 1, 4, 5, and 6 were obtained with the described methods [57, 58 ] from 8-unsubstituted xanthines via 2-or 3-step procedures involving bromination of theophylline. The start-ing material for the syntheses of compounds 2, 3 was 8-(hydroxybenzyl)theophylline received from 5,6-diamino-1,3-dimethyluracil.
Spatial properties of the obtained compounds were examined by X-ray structure determination. Conformational analysis of the oxygen containing groups 1, 2, and 3 performed by 1 H-NMR method in solution or by AM1 and ab initio calculations allowed to state that oxazoline ring is practically coplanar, while oxazine (2) and oxazepine (3) rings may adopt various conformations [57] .
For chiral recognition of the compounds possessing in their structures chiral centers, the dirhodium method was successfully applied. The way of complexation was studied as well in solution as in solid state. It was shown by IR and NMR studies that compounds from groups 1, 2, 3, and 5 prefer a side-on complexation of the central imidazole unit to the chiral dirhodium complex in solution, whereas carbonyl groups are involved in the solid state [56, 57] .
Physicochemical properties of the obtained compounds were examined on basis of theoretical (pK a , log P, log D) calculations and practical experiments (HPLC, TLC). The synthesized compounds were evaluated in in vitro receptor binding studies for the affinity at A 1 [59] for hA 3 ARs) were shown to be A 2A selective vs. all other AR subtypes (Fig. 7) . The most potent and selective ligands investigated for their antagonistic properties [60] in the radioligand binding studies in the presence of Na + ions were classified as antagonists for A 2A AR. The compounds were also tested in vivo according to the National Institutes of Health's Antiepileptic Drug Development Program in Bethesda, Maryland, USA (Table 1) [61, 62] . They were generally active as anticonvulsants mainly in chemical induced seizures (ScMet). Some of them (with shorter substituents 5b-5d) exhibited neurotoxicity (clonic seizures, tonic extension, and death). The most potent butyl 5e and methoxyalkyl derivatives 5o, 5r were advanced for further investigations.
Structure-AR activity relationships for 1-6 revealed that oxygen-containing tricylic derivatives 1, 2, and 3 are moderately potent AR antagonists exhibiting selectivity either for A 1 or A 2A ARs; tricyclic purindiones with nitrogen in the third ring are generally more A 2A selective; and cycloalkyl substituents increase A 2A affinity and selectivity ( Table 1 ). The most potent compound of the present series is N-(methylcyclohexyl)-substituted pyrimido-purindione 5m (K i A 2A = 240 nM, >100-fold selectivity), the compound was slightly less potent at human as compared to rat A 2A ARs (Fig. 8) . There was no apparent correlation between anticonvulsant activity and AR affinity.
Concluding, new classes of tricyclic AR antagonists were identified and characterized, which can be envisaged as configurationally stable analogs of 8-styrylxanthines. Further efforts to optimize the affinity and selectivity of these new classes of AR antagonists applying also QSAR methods are in progress.
